Update of Pharmacy Drug Coverage for Treatment of Obesity (GLP-1 receptor agonist medications)
Customize your policy alerts
Sign up for mclaren health plan Policy MSA 21-49 alerts
Get alerted when Policy MSA 21-49 changes without checking for updates manually.
Monitor payer policy activity
Updates Medicaid pharmacy coverage and prior authorization requirements for GLP-1 receptor agonist medications when prescribed solely for treatment of obesity; affects prescribers, pharmacies, and Medicaid beneficiaries covered under the referenced plan.
Coverage of GLP-1 medications prescribed solely to treat obesity will be reduced effective January 1, 2026.
Clinical PA criteria will require patients to be classified as morbidly obese and to have documented failure of all other clinically appropriate weight-loss interventions, and coverage should be considered to avert need for bariatric surgery.
Some GLP-1 medications (e.g., Saxenda and Wegovy) will become non-preferred on the Single Preferred Drug List starting January 1, 2026, affecting copayment amounts.
Coverage for GLP-1 medications for non-obesity indications will not change.
Coverage Criteria for GLP-1 Medications Prescribed Solely for Obesity
Clinical PA criteria for obesity-only GLP-1 coverage
Covered when ALL of the following are met:
From policy: patient must be classified as morbidly obese.
Coverage is contingent on documented failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred agents).
Policy specifies coverage must be considered only to avert bariatric surgery.
Requests for GLP-1 receptor agonist medications submitted for indications other than treatment of obesity are not affected by this policy change and will continue to be processed according to their existing coverage criteria and indications. The policy change specifically targets GLP-1 use when prescribed solely to treat obesity; other approved uses remain covered.
Requests for GLP-1 medications submitted solely for weight loss that do not meet the updated obesity-only clinical requirements are not covered. Specifically, coverage for obesity-only requests will be reduced effective January 1, 2026, and prior authorization for these requests will require that the patient be classified as morbidly obese and have documented failure of all other clinically appropriate weight-loss interventions; requests that lack these elements risk denial.
Drugs and Coding References
| Liraglutide | generic for Saxenda |
| Saxenda | Saxenda |
| Wegovy | Wegovy |
| Zepbound | Zepbound |
| NDC or specific codes not listed | Document lists example products but does not provide NDCs or billing codes. |
Provider Authorization, Documentation, and Denial Triggers
Obesity-only GLP-1 requests require prior authorization
Prior authorization is required for GLP-1 receptor agonist medications when they are requested solely to treat obesity; clinical PA criteria will apply and be posted on the pharmacy website.
Step therapy: must document failure of other weight‑loss interventions
Coverage for GLP-1 medications prescribed solely for obesity is contingent on documented failure of all other clinically appropriate weight‑loss interventions, including trial and failure of PDL‑preferred anti‑obesity agents.
PA documentation must show morbid obesity and prior‑failure history
Clinical documentation submitted with PA requests must demonstrate the patient is classified as morbidly obese, document failure of all other clinically appropriate weight‑loss interventions (including trials of PDL‑preferred agents), and state that the medication is being considered to avert bariatric surgery.
Denial risk if morbid obesity or prior‑failure criteria are not met
Requests for GLP-1 medications prescribed solely for weight loss that do not meet the morbid obesity classification or lack documented failure of other weight‑loss interventions risk denial under the updated criteria.
Background and Policy Scope
GLP-1 receptor agonists are a drug class used for weight loss and for other clinical indications. This policy narrows Medicaid coverage for GLP-1 products when prescribed solely to treat obesity by imposing new clinical prior authorization requirements effective January 1, 2026. Under the update, obesity-only coverage will require that the patient be classified as morbidly obese, demonstrate documented failure of all other clinically appropriate weight-loss interventions (including trial and failure of PDL-preferred anti-obesity agents), and that use be considered only to avert higher-cost bariatric surgery. Existing prior authorizations approved before January 1, 2026 will be honored for the remaining six months of their authorized period.
Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.